Phase I study of OSI-774 (NSC 718781) [erlotinib] for solid tumors in patients with hepatic or renal dysfunction.

Trial Profile

Phase I study of OSI-774 (NSC 718781) [erlotinib] for solid tumors in patients with hepatic or renal dysfunction.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2013

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Anal cancer; Bladder cancer; Breast cancer; Cervical cancer; Colorectal cancer; Head and neck cancer; Liver cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 15 Sep 2009 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 31 Dec 2008 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
    • 28 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top